<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474562</url>
  </required_header>
  <id_info>
    <org_study_id>YMC032</org_study_id>
    <nct_id>NCT03474562</nct_id>
  </id_info>
  <brief_title>High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension</brief_title>
  <official_title>Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or
      amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 24 in homeostasis model assessment for insulin resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in HOMA-IR</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in insulin level</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in homeostatic model assessment for β-cell function (HOMA-B)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in C-reactive protein (CRP)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ASCVD</condition>
  <condition>Impaired Fasting Glucose</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Duowell Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monorova Tab + Amlopin Tab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duowell®</intervention_name>
    <description>Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP &gt; 140mmHg or DBP &gt; 90mmHg at week 12)</description>
    <arm_group_label>Duowell Tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monorova® + Amlopin®</intervention_name>
    <description>Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP &gt; 140mmHg or DBP &gt; 90mmHg at week 12)</description>
    <arm_group_label>Monorova Tab + Amlopin Tab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Aged 19 to 75 years

          3. Patients with ASCVD requiring high-intensity statin therapy (in accordance with the
             clinical ASCVD diagnostic criteria in the 2013 ACC/AHA Guideline)

             - Coronary artery disease

               -  acute coronary syndrome

               -  history of myocardial infarction (MI)

               -  stable or unstable angina

               -  history of coronary revascularization

               -  stroke or transient ischemic attack (TIA)

               -  peripheral arterial disease, history of peripheral arterial revascularization

          4. Those who are taking antihypertensive drugs, or SBP &gt; 140mmHg or DBP &gt; 90mmHg on the
             left side

          5. High-risk group (except for gestational diabetes) who has not been diagnosed with
             diabetes before, and who falls under one of the following criteria:

               -  impaired fasting glucose (IFG): 100-125 mg/dL (5.6-6.9 mmol/L)

               -  impaired glucose tolerance (IGT): plasma blood glucose 140-199mg/dL (7.8 to 11.0
                  mmol/L) 2 hours after oral administration of glucose 75g

        Exclusion Criteria:

          1. Those who are treated with secondary hypertension or malignant hypertension

          2. Uncontrollable diabetes with HbA1c ≥ 10%

          3. Total cholesterol ≥ 300mg/dL

          4. Fasting LDL-C ≤ 70 mg/dL

          5. Fasting triglyceride ≥ 500 mg/dL

          6. History of muscular disease or rhabdomyolysis due to use of statin

          7. Hypersensitive to statin or ARBs

          8. Contraindications stated in the SPC of telmisartan or rosuvastatin including the
             following:

               -  severe renal disease (CrCL &lt; 30mL/min: Cockcroft-gault formula or estimated GFR
                  (MDRD) &lt; 30mL/min/1.73m2)

               -  ALT, AST &gt; 3x ULN or history of active liver disease

               -  CPK &gt; 3x ULN

               -  hyperkalemia with serum K &gt; 5.5 mEq/l

          9. Those who are participating in clinical trials of other investigational products

         10. Those who cannot discontinue all other treatment for hypertension or hyperlipidemia
             than the investigational products, and concomitant medications and supplements that
             can affect the therapeutic effect of hypertension and hyperlipidemia during the trial
             period

         11. Other than the above who is deemed to be ineligible to participate in the trial by
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

